TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

August 31, 2027

Conditions

GVHD, Chronic

Interventions

DRUG

TDI01 suspension

200mg or 400mg oral once a day

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Beijing Tide Pharmaceutical Co., Ltd

INDUSTRY

NCT06169722 - TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) | Biotech Hunter | Biotech Hunter